Table 1.
Current Treatments with Survival Benefit for Patients with Prostate Cancer.
| Brand Name | Generic Name | Approval Date | Treatments | Category |
|---|---|---|---|---|
| Taxotere | Docetaxel in combination with prednisone | 19 May 2004 | mCRPC | Chemotherapy |
| Jevtana | Cabazitaxel in combination with prednisone | 17 June 2010 | mCRPC after docetaxel |
Chemotherapy |
| Xofigo | radium-223 | 15 May 2013 | mCRPC | Radiotherapy |
| Provenge | Sipuleucel-T | 29 April 2010 | Asymptomatic or minimally symptomatic mCRPC | Immunotherapy |
| Zytiga | Abiraterone acetate in combination with prednisone | 28 April 2011 | mCRPC after docetaxel |
Hormonal therapy |
| Zytiga | Abiraterone acetate in combination with prednisone | 10 December 2012 | mCRPC before chemotherapy |
Hormonal therapy |
| Zytiga | Abiraterone acetate in combination with prednisone | 7 February 2018 | mCSPC | Hormonal therapy |
| Erleada | Apalutamide | 14 February 2018 | nmCRPC | Hormonal therapy |
| Erleada | Apalutamide | 17 September 2019 | mCSPC | Hormonal therapy |
| XTANDI | Enzalutamide | 31 August 2012 | mCRPC after docetaxel |
Hormonal therapy |
| XTANDI | Enzalutamide | 13 July 2018 | nmCRPC | Hormonal therapy |
| NUBEQA | Darolutamide | 30 July 2019 | nmCRPC | Hormonal therapy |
| XTANDI | Enzalutamide | 16 December 2019 | mCSPC | Hormonal therapy |
nmCRPC: non-metastatic castration-resistant prostate cancer. mCRPC: metastatic castration-resistant prostate cancer mCSPC: metastatic castration-sensitive prostate cancer.